Background Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease was published in 2014 for a multidisciplinary audience. Following this, a companion guide to managing upper gastrointestinal (GI) consequences was developed. Aims The development and peer review of an algorithm which could be accessible to all types of clinicians working with patients experiencing upper GI symptoms following cancer treatment. Methods Experts who manage patients with upper GI symptoms were asked to review the guide, rating each section for agreement with the recommended measures and suggesting amendments if necessary. Specific comments were discussed and incorporated as appropriate, and this process was repeated for a second round of review. Results 21 gastroenterologists, 11 upper GI surgeons, 9 specialist dietitians, 8 clinical nurse specialists, 5 clinical oncologists, 3 medical oncologists and 4 others participated in the review. Consensus (defined prospectively as 60% or more panellists selecting 'strongly agree' or 'agree') was reached for all of the original 31 sections in the guide, with a median of 90%. 85% of panellists agreed that the guide was acceptable for publication or acceptable with minor revisions. 56 of the original 61 panellists participated in round 2. 93% agreed it was acceptable for publication after the first revision. Further minor amendments were made in response to round 2. Conclusions Feedback from the panel of experts developed the guide with improvement of occasional algorithmic steps, a more userfriendly layout, clearer time frames for referral to other teams and addition of procedures to the appendix.
INTRODUCTION
This guide is designed for all clinicians who look after people who have been treated for upper gastrointestinal (GI) cancer. It is also designed for patients who are experiencing upper GI symptoms following any cancer treatment. Some of these will be doctors, others may be senior nurses and increasingly, other allied health professionals.
Some lower GI symptoms are also included because these are common after treatment for upper GI cancers. However, for more detailed advice about managing lower GI symptoms please refer to Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease. 1 The GI consequences of chemotherapy, radiotherapy and resectional surgery are not that different. Historically, clinicians have associated specific clusters of symptoms with typical diagnoses especially in patients who have been treated for upper GI and hepatopancreatobiliary cancer. Research increasingly suggests that specific symptoms are not reliable indicators of the underlying cause, hence, this algorithmic approach.
This guide defines best practice although not every investigation modality or treatment may be available in every hospital.
Those using the guide, especially if non-medically qualified, should identify a senior gastroenterologist or other appropriately qualified and experienced professionals whom they can approach easily for advice if they are practicing in an unsupervised clinic.
Practitioners should not use this guide outside the scope of their competency and must identify from whom they will seek advice about abnormal test results which they do not fully understand before using the guide.
Specific therapies are usually not listed by name but as a 'class' of potential drugs as different clinicians may have local constraints or preferences as to the medications available.
Arranging all first line suggested investigations required by the symptom(s) at the first consultation reduces follow-up and allows directed treatment of all causes of symptoms at the earliest opportunity. Timely review of requested investigations is required so that further investigations can be requested if required. If worrying symptoms are elicited or potentially abnormal findings are present on clinical examination, then the order of investigations suggested in the algorithm may no longer be appropriate.
Practitioners seeing these patients are encouraged to consider providing patients with symptom questionnaires including nutritional screening questions to complete before or during the consultation as this may help improve the choice of investigations and identify when referral is required.
This guide has three parts:
1. An introduction, instructions how to use the algorithm, guide to blood tests and taking a history. 2. An algorithm detailing the individual investigations and treatment of each of the 28 GI symptoms.
3. Appendices with brief descriptions of the diagnosis, treatment and management techniques available.
HOW TO USE THE ALGORITHM
1. Up to 28 symptoms have been described in this patient group. 2. Each symptom may have more than one contributing cause. 3. Symptoms must be investigated systematically otherwise causes will be missed. 4. Identify the symptoms by systematic history taking. 5. Examine the patient appropriately. 6 . Use the algorithm to plan investigations. 7. Most patients have more than one symptom and investigations need to be requested for each symptom. 8. Usually all investigations are requested at the same time and the patient reviewed with all the results. 9. When investigations should be ordered sequentially, the algorithm indicates this by stating first line, second line, etc. 10. Treatment options are generally offered sequentially but clinical judgement should be used.
GUIDE TO USING BLOOD TESTS
Routine blood tests include: full blood count, urea and electrolytes, liver function, glucose, calcium (table 1) . Additional blood tests are indicated depending on the presenting GI symptoms and differential diagnoses as outlined in the algorithm (table 2). 
Abnormal liver function tests (new onset)
▸ Discuss with supervising clinician within 24 hours. ▸ Check thyroid function ▸ Patient will need a liver ultrasound and liver screen including hepatitis A, B, C and E serology, EBV and CMV, ferritin, α feta protein, α 1 antitrypsin, coeliac serology, liver autoantibodies, total Igs, cholesterol, triglycerides, caeruloplasmin (<50 years old only). Abnormal liver function tests (long standing) ▸ Refer for further evaluation to a hepatologist.
Abnormal glucose level
▸ If no history of diabetes: Between 7-11 mmol/L: refer to GP. >11 mmol/L and ketones in urine: this is an emergency. >11-20 mmol and no ketones in urine: discuss with supervising clinician within 24 hours. >20 mmol/L and no ketones in urine: this is an emergency. ▸ If known diabetic:
Do not check glucose levels. Consider checking glycosylated haemoglobin (HbAIC). Abnormal corrected calcium level ▸ If 2.6-2.9 mmol/L: discuss with supervising clinician within 24 hours.
▸ If <1.8 mmol/L or >3.0 mmol/L: this is an emergency. ▸ Check parathyroid hormone levels.
CMV, cytomegalovirus; EBV, Epstein-Barr virus; GP, general practitioner; K, potassium; Na, sodium; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); RBC, red blood cell; SI, small intestine. Ca, calcium; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; GP, general practitioner; IBD, inflammatory bowel disease; K, potassium; Mg, magnesium; Na, sodium; PO 4 , phosphate; RBC, red blood cell; SIBO, small intestinal bacterial overgrowth; TSH, thyroid stimulating hormone; TTG, tissue transglutaminase. (table 2) .
Specific tests are indicated depending on the symptoms/diagnosis as outlined in the algorithm.
They may include fat soluble vitamins, trace elements, fasting gut hormones, international normalised ratio, haematinics (table 3) .
TAKING AN APPROPRIATE HISTORY
Patients cannot be helped without an accurate history being taken.
▸ Taking a history of GI symptoms is a skill that must be learnt. ▸ Specialist units find that symptom questionnaires completed by the patient before the consultation often help clarify which issues are really troubling the patient. ▸ Take a broad approach: for example, after treatment for upper GI cancer, patients also frequently develop troublesome lower GI symptoms. figure 3 and table 6 ). Refer to dietitian for a trial of low FODMAPs diet.
Fifth line If no response to intervention
Referral for gastroenterology for small bowel motility studies. Reassure. AXR, abdominal X-ray; CT, computerised tomography; EPI, exocrine pancreatic insufficiency; FODMAPs, fermentable oligo-di-monosaccharides and polyols; GI, gastrointestinal; MDT, multidisciplinary team; MRI, magnetic resonance imaging; NSAID, non-steroidal anti-inflammatory drug; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); SI, small intestine; SIBO, small intestinal bacterial overgrowth; US, ultrasound.
BORBORYGMI

Rumbling/gurgling noises in the abdomen (Supplementary figure 4 and table 7).
CHANGE IN SENSE OF SMELL (hyposmia, anosmia or parosmia)
The reduced ability, inability or distortion of sensation of odour (Supplementary figure 5 and table 8). 5HIAA, 5-hydroxyindole acetic acid; AXR, abdominal X-ray; CT, computerised tomography; GI, gastrointestinal; MDT, multidisciplinary team; NET, neuroendocrine tumour; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); SIBO, small intestinal bacterial overgrowth. CT, computerised tomography; ENT, ear, nose and throat; MDT, multidisciplinary team; MRI, magnetic resonance imaging; PET, positron emission tomography. Refer to the appropriate MDT requesting an appointment within 2 weeks.
Third line If normal investigations/no response to intervention
Reassure.
CT, computerised tomography; GORD, gastro-oesophageal reflux disease; H2, histamine receptor 2; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PET, positron emission tomography; PPI, proton pump inhibitor. 
Fifth line
If normal investigations/no response to intervention
ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; CT, computerised tomography; CTPA, CT pulmonary angiography; CXR, chest X-ray; ENT, ear, nose and throat; GORD, gastro-oesophageal reflux disease; GP, general practitioner; H2, histamine -2; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PPI, proton pump inhibitor; SLT, speech and language therapy.
DIARRHOEA
Stool type 6-7 on the Bristol stool chart. 3 Not increased frequency of type 1-5 (Supplementary figure 8 and table 11 ). (Supplementary figure 9 and table 12 ) DUMPING For dumping, please refer to the section 'Postprandial dizziness/sweating/palpitations' on page 20.
DRY MOUTH (xerostomia)
DYSPHAGIA-HIGH (oropharyngeal dysphagia).
Difficulty with swallowing/sensation of food sticking (Supplementary figure 10, tables 13 and 14) . 
General advice
Oral hygiene: refer to dentist/oral hygienist. Use fluoridated toothpaste-all dentate patients should use toothpaste with at least 1000 ppm fluoride, while dentate patients with radiation-induced salivary gland dysfunction should use specialist toothpaste with 5000 ppm fluoride. Limit acidic and sugary drinks/foods/medication and rinse mouth after these products. Symptomatic management 4 1. Consider saliva substitutes, eg, artificial saliva spray or lozenges (mucin based) or a non-porcine alternative, if required for cultural reasons. Note: Glandosane spray, Salivix pastilles and SST tablets are acidic products and may demineralise tooth enamel. 2. Consider mechanical salivary stimulants:
▸ Sugarless chewing gum/mints. ▸ Pilocarpine 5 mg three times a day in patients treated with radiotherapy to the head and neck. Consider referral for acupuncture. Refer to oral surgery. GP, general practitioner; SSRI, selective serotonin reuptake inhibitor; SST, saliva stimulating tablet. CT, computerised tomography; ENT, ear, nose and throat; GI, gastrointestinal; MDT, multidisciplinary team; NSAID, non-steroidal anti-inflammatory drug; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PET, positron emission tomography; SLT, speech and language therapy. CT, computerised tomography; GI, gastrointestinal; H2, histamine receptor 2; MDT, multidisciplinary team; NSAID, non-steroidal anti-inflammatory drug; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PET, positron emission tomography; PPI, proton pump inhibitor; SIBO, small intestinal bacterial overgrowth; SLT, speech and language therapy. figure 12 and table 17 ).
EARLY SATIETY Feeling full after eating a small amount of food (Supplementary
EPIGASTRIC PAIN CHRONIC (>2 weeks)
Pain localised to the region of the upper abdomen immediately below the ribs (Supplementary figure 13 and table 18 ). 
Second line
Barium meal Pyloric spasm/stricture Consider dilatation (p. 25) with careful biopsy only after agreement from the appropriate MDT.
Third line
Gastric emptying study Delayed gastric emptying ▸ Assess for SIBO. ▸ Consider prokinetic (p. 26). ▸ Pyloric dilatation if after oesophagectomy. ▸ Referral to dietitian.
Fourth line
If normal investigations/no response to intervention
CT, computerised tomography; GP, general practitioner; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); SI, small intestine; SIBO, small intestinal bacterial overgrowth. GI BLEEDING (haematemesis and/or melaena) Vomiting blood or 'coffee grounds' and/or black 'tarry' faeces associated with upper GI bleeding (Supplementary figure 14 and table 19 ). AXR, abdominal X-ray; CT, computerised tomography; CXR, chest X-ray; GI, gastrointestinal; H2, histamine receptor 2; MDT, multidisciplinary team; MRI, magnetic resonance imaging; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PET, positron emission tomography; PPI, proton pump inhibitor; SIBO, small intestinal bacterial overgrowth; US, ultrasound. figure 15 and table 20) . 
HALITOSIS
An unpleasant odour emitted from the mouth (Supplementary
HICCUPS (singultus) (Supplementary figure 16 and table 21)
Third line
Contrast swallow Pharyngeal pouch
Refer to the ENT/oesophageal surgeon.
Fourth line
If normal investigations/no response to intervention
Refer to oral medicine.
ENT, ear, nose and throat; GI, gastrointestinal; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PPI, proton pump inhibitor; SIBO, small intestinal bacterial overgrowth. CT, computerised tomography; ENT, ear, nose and throat; GI, gastrointestinal; GORD, gastro-oesophageal reflux disease; H2, histamine -2; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PPI, proton pump inhibitor. CT, computerised tomography; ENT, ear, nose and throat; GORD, gastro-oesophageal reflux disease; H2, histamine receptor 2; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PPI, proton pump inhibitor; SLT, speech and language therapy. figure 18 and table 23 ).
HYPERSALIVATION/DROOLING
(sialorrhoea) present longer than 3 weeks Production of excessive oral secretions which are not swallowed (Supplementary
JAUNDICE
Yellowish pigmentation of the skin, the conjunctival membranes over the sclerae and other mucous membranes caused by high blood bilirubin levels (Supplementary figure 19 and table 24 ). GORD, gastro-oesophageal reflux disease; H2, histamine receptor 2; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PPI, proton pump inhibitor. Discuss with the gastroenterology or hepatology team within 24 hours. Warn the patient that if they develop a fever they need to seek immediate medical help. FBC, full blood count; INR, international normalised ratio; LFTs, liver function tests; U&E, urea and electrolytes; US, ultrasound.
NAUSEA WITHOUT DYSPHAGIA Feeling of sickness in the stomach marked by an urge to vomit. If dysphagia is present with nausea, follow dysphagia guidance in tables 14 and 16. Reassure. CMV, cytomegalovirus; GI, gastrointestinal; H2, histamine receptor 2; HSV, herpes simplex virus; MDT, multidisciplinary team; NSAID, non-steroidal anti-inflammatory drug; OGD, upper GI endoscopy (oesophago-gastroduodenoscopy); PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor. In gastro-oesophageal reflux, acid refluxes from the stomach into the oesophagus. In duodenogastric reflux, bile refluxes from the duodenum into the stomach and oesophagus (Supplementary figure 23 and table 28 ). 
REGURGITATION
The expulsion of material from the mouth, pharynx or oesophagus, usually characterised by the presence of undigested food (Supplementary figure 24 and table 29) .
STEATORRHOEA
The presence of excess fat in the stool. Stools may float, be difficult to flush away and have an oily appearance. Sometimes pale (chalk/sand) in colour. Sometimes an oily film can be seen in the lavatory water after defaecation (Supplementary figure 25 and ENT, ear, nose and throat; GI, gastrointestinal; H2, histamine receptor 2; MDT, multidisciplinary team; OGD, upper GI endoscopy (oesophagogastroduodenoscopy); PET, positron emission tomography; PPI, proton pump inhibitor; SIBO, small intestinal bacterial overgrowth; US, ultrasound. need a bile acid sequestrant and advice about longterm reduction in dietary fat intake. 13 Drugs that may be helpful include aluminium hydroxide, budesonide, colesevelam, colestipol and colestyramine.
Patients with steatorrhoea usually require colesevelam. If dietary intervention is required, advice to reduce dietary fat intake to 20% of total calories can be useful but requires dietetic expertise, patient education and supportive literature.
Many patients with moderate/severe BAM/BAD will be deficient in trace elements and fat soluble vitamins. These should be checked periodically and supplemented as appropriate.
MANAGEMENT OF CARBOHYDRATE MALABSORPTION For example, lactose or other disaccharide intolerance.
Definition
Intolerance occurs from the inability to digest carbohydrates. Lactose, a component of milk and some other dairy products, is the intolerance most frequently recognised. It is due to lack of the enzyme lactase in the small intestine. Primary hypolactasia affects 70% of the world's population. Lactose or other disaccharide or monosaccharide (eg, fructose) malabsorption may occur de novo during cancer therapies (such as 5-fluorouracil chemotherapy or radiotherapy), due to damage to brush border enzymes and in some patients persists in the long term. 14 15 Diagnosis of carbohydrate intolerance ▸ Trial of exclusion of products containing that specific carbohydrate in diet for 1-2 weeks. Patient to keep a record of symptoms before and during the exclusion. ▸ Specific carbohydrate breath test. Maybe falsely positive in the presence of small intestinal bacterial overgrowth (SIBO). ▸ Small intestine biopsies and assessment for the specific disaccharide or monosaccharide activity.
Treatment
▸ Long-term exclusion of products containing the carbohydrate in diet. ▸ Dietetic assessment to ensure diet remains balanced.
With lactose intolerance special attention should be paid to calcium intake. Other bone health risk factors should also be considered and vitamin and mineral supplementation started as appropriate.
14 ▸ Consideration of a low fermentable oligo-di-monosaccharides and polyols diet. ▸ Oral lactases for isolated lactose intolerance. Medicines & Healthcare Products Regulatory Agency (MHRA) has issued a number of warnings about the risks of using some of these medications for a longer period.
MANAGEMENT OF CONSTIPATION
20
Prescribers should be aware of local policies with regard to the use of these drugs.
MANAGEMENT OF SIBO
Definition SIBO is the presence of excessive bacteria in the small intestine. Small bowel bacterial overgrowth is a common cause for any GI symptom after chemotherapy and upper GI surgery. For any symptom resistant to conventional treatment, consider the possibility of SIBO.
Diagnosis
▸ There is no gold standard for diagnosing SIBO. 21 22 ▸ Glucose hydrogen methane breath testing±small intestine aspirate ( p. 25) via upper GI endoscopy. ▸ Red blood cell (RBC) folate and total serum bile acid levels may be elevated and vitamin B 12 levels and faecal elastase may be low. ▸ 10-15% patients with negative tests still have SIBO. ▸ Ciprofloxacin 500 mg twice daily. ▸ Clarithromycin 500 mg twice daily. ▸ Co-amoxiclav 625 mg three times a day. ▸ Doxycycline 200 mg day 1, 100 mg days 2-7/10. ▸ Metronidazole 400 mg three times a day. ▸ Rifaximin 550 mg twice daily.
▸ Vancomycin 250 mg four times a day.
Symptoms can recur any time after antibiotics are stopped because the underlying cause of bacterial overgrowth cannot always be addressed. If symptoms return, repeat treatment with antibiotics for a few days every month or continually at the lowest effective dose may be helpful in managing symptoms in the long term. Some clinicians recommend rotating antibiotics but this may not be effective if the organisms involved are not sensitive to the antibiotics used.
Treatment decisions should be individualised and consider the risks of long-term antibiotic therapy such as Clostridium difficile infection, cumulative irreversible neuropathy with metronidazole, Achilles tendon rupture with ciprofloxacin, intolerance, side effects, bacterial resistance and costs. 14 
